Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
HIV Medicine|March 16, 2012
Effect of gender and race on the week 48 findings in treatment-naïve, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVES Hodder, K Arasteh, J De Wet, et al.
AIDS (London, England)|June 6, 2000
The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a randomized, double-blind, trial. CNA3002 European Study TeamC Katlama, B Clotet, A Plettenberg, et al.
AIDS (London, England)|May 1, 1995
A dose comparison study of didanosine in patients with very advanced HIV infection who are intolerant to or clinically deteriorate on zidovudine. German ddI Trial GroupH Jablonowski, K Arasteh, S Staszewski, et al.
Deutsche Medizinische Wochenschrift (1946)|September 23, 2003
[Screening and therapy of anal intraepithelial neoplasia (AIN) and anal carcinoma in patients with HIV-infection]A Kreuter, G Reimann, S Esser, et al.
Journal of Viral Hepatitis|April 26, 2017
HIV-positive men who have sex with men are at high risk of development of significant liver fibrosis after an episode of acute hepatitis CK Steininger, A Boyd, S Dupke, et al.
HIV Clinical Trials|October 9, 2001
GW420867X administered to HIV-1-infected patients alone and in combination with lamivudine and zidovudineK Arasteh, R Wood, M Müller, et al.
Journal of Clinical Microbiology|February 1, 1996
High-level sensitivity of quantitative pp65 cytomegalovirus (CMV) antigenemia assay for diagnosis of CMV disease in AIDS patients and follow-upB Bek, M Boeckh, J Lepenies, et al.
Drug and Alcohol Dependence|September 23, 2018
Hepatitis C virus prevalence and estimated incidence among new injectors during the opioid epidemic in New York City, 2000-2017: Protective effects of non-injecting drug useDon C Des Jarlais, K Arasteh, J Feelemyer, et al.
HIV Medicine|December 6, 2011
Twenty-four-week efficacy and safety of switching virologically suppressed HIV-1-infected patients from nevirapine immediate release 200 mg twice daily to nevirapine extended release 400 mg once daily (TRANxITION)K Arasteh, D Ward, A Plettenberg, et al.
Spine|May 30, 2009
Treatment of spondylodiscitis in human immunodeficiency virus-infected patients: a comparison of conservative and operative therapyR Sobottke, K Zarghooni, M Krengel, et al.
Pageof 5